As Sanofi (SNY) Shares Rose, Barrow Hanley Mewhinney & Strauss LLC Increased Stake

Sanofi (NASDAQ:SNY) Corporate Logo

Barrow Hanley Mewhinney & Strauss Llc increased its stake by 4.9% in Sanofi (SNY), according to 2018Q3 SEC filling. The company’s stock popped up 3.59% while Barrow Hanley Mewhinney & Strauss Llc bought 954,977 shares. At the end of 2018Q3, the 20.43 million shares of the major pharmaceuticals company held by the institutional investor were valued at $912.48M, up from 19.47M at the end of the previous reported quarter. Sanofi has $105.52 billion MC. The stock decreased 0.49% or $0.21 during the last trading session, hitting $42.43.Currently Sanofi is uptrending after 2.03% change in last February 11, 2018. SNY has also 301,737 shares volume. The stock outperformed the S&P500 by 2.03%.

According to a filing the Barrow Hanley Mewhinney & Strauss Llc’s stake in General Dynamics Corp (NYSE:GD) was decreased by 408,260 shares to 2.75M shares valued at $562.32 million in 2018Q3. It operates about $91.02 billion and $63.00B US Long portfolio. Barrow Hanley Mewhinney & Strauss Llc has cut its stake in Spirit Aerosystems Holdings In (NYSE:SPR) and also reduced its holding in Target Corp (NYSE:TGT) by 1.25M shares in the quarter, for a total of 1,642 shares.

For more Sanofi (NASDAQ:SNY) news announced recently go to: Nasdaq.com, Seekingalpha.com, Nasdaq.com, Seekingalpha.com or Streetinsider.com. The titles are as follows: “ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up – Nasdaq” announced on February 11, 2019, “Voyager up 37% premarket on gene therapy deal – Seeking Alpha” on January 29, 2019, “Sanofi’s (SNY) Influenza Vaccine Gets FDA Approval for Kids – Nasdaq” with a publish date: January 24, 2019, “Key events next week – healthcare – Seeking Alpha” and the last “Lexicon Pharma (LXRX), Sanofi (SNY) Diabetes Drug FDA Panel Vote Tied 8-8 – Bloomberg – StreetInsider.com” with publication date: January 17, 2019.

Sanofi (NASDAQ:SNY) Ratings Coverage

In total 4 analysts cover Sanofi (NYSE:SNY). “Buy” rating has 2, “Sell” are 0, while 2 are “Hold”. 50% are bullish. 5 are the (NYSE:SNY)’s analyst reports since August 24, 2018 according to StockzIntelligence Inc. On Thursday, November 1 the firm has “Equal-Weight” rating by Barclays Capital given. On Thursday, November 8 the company was maintained by Argus Research. On Friday, August 24 the stock has “Buy” rating by Argus Research. On Monday, September 10 the rating was upgraded by Bank of America to “Buy”.

Sanofi (NASDAQ:SNY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.